The molecular mechanisms of SMAD3-mediated coronary disease risk
SMAD3介导的冠心病风险的分子机制
基本信息
- 批准号:9609402
- 负责人:
- 金额:$ 6.6万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2018
- 资助国家:美国
- 起止时间:2018-09-15 至 2021-09-14
- 项目状态:已结题
- 来源:
- 关键词:15q22AddressAffectAnatomyArterial Fatty StreakAtherosclerosisBindingBioinformaticsBiologic CharacteristicBiological ProcessBlood VesselsCardiovascular DiseasesCell CountCell Differentiation processCell modelCell physiologyCellsCellular biologyChIP-seqComputational TechniqueCoronary ArteriosclerosisCoronary arteryCoronary heart diseaseDataData SetDevelopmental BiologyDiseaseEmbryoEmbryonic DevelopmentEnhancersFellowshipFutureGene ExpressionGene Expression ProfilingGenesGeneticGenetic RiskGenetic TranscriptionGenetic VariationGoalsGrantHumanLesionLinkMADH3 geneMediatingMentorsModelingMolecularMusPathway interactionsPhenotypePhysiciansPlayPopulationPreventiveProcessRegulationRiskRisk FactorsRoleScientistSeriesSignal PathwaySignal TransductionSiteSmooth MuscleSmooth Muscle MyocytesStimulusStressTherapeuticTrainingTranscriptional RegulationTransforming Growth Factor betaVariantWorkcareerdisorder riskexperimental studygenome wide association studygenome-wide analysisin vivoinnovationmouse modelnovel therapeutic interventionnovel therapeuticsprogenitorprogramsresponserisk variantskillsstem cellstranscription factortranscriptometranscriptome sequencing
项目摘要
Project Summary
Despite major advances in therapies, coronary artery disease (CAD) remains the leading killer in the US and
worldwide. Identification of risk factors and understanding their underlying biological processes are urgently
needed to develop innovative new therapies. Numerous genetic loci have been associated with an increased
risk for coronary artery disease (CAD) in genome wide association studies (GWAS). Now efforts are needed to
identify causal genes in these loci and link them to specific cellular processes and signaling pathways.
Smooth muscle cells (SMC) in the vascular wall express a majority of CAD-associated genes identified
in GWAS. Recently, SMAD3 has been identified as the CAD causal association at 15q22.33. Developmental
biology as well as our preliminary data suggest SMAD3 may modify cell-fate decisions of phenotypically
modulated SMC in the vascular walls in the setting of vascular stress. This led to our central hypothesis that
SMAD3 governs a transcriptional network that inhibits protective SMC phenotypic modulation in response to
vascular stress. The series of experiments described herein aim to characterize the cellular mechanisms by
which perturbation of smooth muscle Smad3 expression modulates atherosclerotic lesions, as well as identify
the genetic program regulated by SMAD3 in human coronary artery smooth muscle cells. Aim 1 utilizes a
murine atherosclerosis model with SMC-specific deletion of Smad3 and concurrent lineage tracing. We will
investigate the effect of Smad3 expression on SMC cell fate and resulting disease anatomy. We will then apply
single cell transcriptional profiling of lesion cells to examine the transcriptional program in different SMC
progenies, and combine these datasets to understand how CAD risk is mediated by Smad3 specifically in SMC
at the cellular level. Aim 2 applies a human coronary artery smooth muscle cell model to study the
transcriptional program regulated by SMAD3 through genome-wide identification of enhancers bound by
SMAD3 and their transcriptional regulatory effects. We will also overlap the finding with data from another
smooth-muscle-expressed CAD-risk-associated transcription factor TCF21, to further our understanding of the
SMC transcriptional program that regulates CAD risk. Together, these studies will significantly expand our
understanding of the role of transcription factors SMAD3 and TCF21 expressed by SMCs in CAD, and
significantly advance our understanding of mechanisms by which causal variation mediates risk for CAD with
the hope of leading to novel therapeutic strategies in the future.
项目概要
尽管治疗方法取得了重大进展,但冠状动脉疾病 (CAD) 仍然是美国的头号杀手
全世界。识别风险因素并了解其潜在的生物过程刻不容缓
需要开发创新的新疗法。许多遗传位点与增加
全基因组关联研究(GWAS)中冠状动脉疾病(CAD)的风险。现在需要努力
识别这些基因座中的因果基因并将它们与特定的细胞过程和信号通路联系起来。
血管壁中的平滑肌细胞 (SMC) 表达大多数已确定的 CAD 相关基因
在 GWAS 中。最近,SMAD3 已被确定为 15q22.33 的 CAD 因果关联。发育性
生物学以及我们的初步数据表明 SMAD3 可能会改变表型的细胞命运决定
在血管应激的情况下调节血管壁中的 SMC。这导致我们的中心假设是
SMAD3 控制转录网络,抑制保护性 SMC 表型调节以响应
血管应激。本文描述的一系列实验旨在通过以下方式表征细胞机制:
平滑肌 Smad3 表达的扰动可调节动脉粥样硬化病变,并确定
人类冠状动脉平滑肌细胞中由 SMAD3 调节的遗传程序。目标 1 利用
具有 SMC 特异性删除 Smad3 和并发谱系追踪的小鼠动脉粥样硬化模型。我们将
研究 Smad3 表达对 SMC 细胞命运和由此产生的疾病解剖学的影响。然后我们将申请
对病变细胞进行单细胞转录分析,以检查不同 SMC 中的转录程序
后代,并结合这些数据集来了解 CAD 风险如何由 Smad3 特别是在 SMC 中介导
在细胞水平上。目标2应用人冠状动脉平滑肌细胞模型来研究
SMAD3 通过全基因组识别增强子来调节转录程序
SMAD3 及其转录调控作用。我们还将这一发现与另一个数据重叠
平滑肌表达的 CAD 风险相关转录因子 TCF21,以进一步了解
调节 CAD 风险的 SMC 转录程序。总之,这些研究将显着扩展我们的
了解 SMC 表达的转录因子 SMAD3 和 TCF21 在 CAD 中的作用,以及
显着增进我们对因果变异介导 CAD 风险机制的理解
希望在未来产生新的治疗策略。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Paul Po Sheng cheng其他文献
Paul Po Sheng cheng的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Paul Po Sheng cheng', 18)}}的其他基金
From Locus to Function: Role of ZEB2 in Human Risk of Coronary Artery Disease
从基因座到功能:ZEB2 在人类冠状动脉疾病风险中的作用
- 批准号:
10241961 - 财政年份:2020
- 资助金额:
$ 6.6万 - 项目类别:
From Locus to Function: Role of ZEB2 in Human Risk of Coronary Artery Disease
从基因座到功能:ZEB2 在人类冠状动脉疾病风险中的作用
- 批准号:
10666553 - 财政年份:2020
- 资助金额:
$ 6.6万 - 项目类别:
From Locus to Function: Role of ZEB2 in Human Risk of Coronary Artery Disease
从基因座到功能:ZEB2 在人类冠状动脉疾病风险中的作用
- 批准号:
10469431 - 财政年份:2020
- 资助金额:
$ 6.6万 - 项目类别:
From Locus to Function: Role of ZEB2 in Human Risk of Coronary Artery Disease
从基因座到功能:ZEB2 在人类冠状动脉疾病风险中的作用
- 批准号:
10900886 - 财政年份:2020
- 资助金额:
$ 6.6万 - 项目类别:
From Locus to Function: Role of ZEB2 in Human Risk of Coronary Artery Disease
从基因座到功能:ZEB2 在人类冠状动脉疾病风险中的作用
- 批准号:
10038543 - 财政年份:2020
- 资助金额:
$ 6.6万 - 项目类别:
相似海外基金
Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
- 批准号:
MR/S03398X/2 - 财政年份:2024
- 资助金额:
$ 6.6万 - 项目类别:
Fellowship
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
- 批准号:
EP/Y001486/1 - 财政年份:2024
- 资助金额:
$ 6.6万 - 项目类别:
Research Grant
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
- 批准号:
2338423 - 财政年份:2024
- 资助金额:
$ 6.6万 - 项目类别:
Continuing Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
- 批准号:
MR/X03657X/1 - 财政年份:2024
- 资助金额:
$ 6.6万 - 项目类别:
Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
- 批准号:
2348066 - 财政年份:2024
- 资助金额:
$ 6.6万 - 项目类别:
Standard Grant
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
- 批准号:
2341402 - 财政年份:2024
- 资助金额:
$ 6.6万 - 项目类别:
Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
- 批准号:
AH/Z505481/1 - 财政年份:2024
- 资助金额:
$ 6.6万 - 项目类别:
Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10107647 - 财政年份:2024
- 资助金额:
$ 6.6万 - 项目类别:
EU-Funded
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10106221 - 财政年份:2024
- 资助金额:
$ 6.6万 - 项目类别:
EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
- 批准号:
AH/Z505341/1 - 财政年份:2024
- 资助金额:
$ 6.6万 - 项目类别:
Research Grant